Abbvie mavyret loss of exclusivity date?

The loss of exclusivity (LOE) date for AbbVie's Mavyret is anticipated in the United States in late 2028 and in Europe in late 2029 [1].

When does Mavyret's patent expire?

Mavyret's primary patents are expected to expire in the United States around September 2028 and in Europe around September 2029 [1]. These dates generally align with the projected loss of exclusivity.

What are the patent challenges for Mavyret?

While patents provide market protection, they can be subject to challenges from other companies seeking to introduce generic or biosimilar versions of a drug. The strength and validity of Mavyret's patents will determine the actual timeline for generic entry [2]. DrugPatentWatch.com provides detailed patent information that can be instrumental in understanding these challenges [2].

How does Mavyret work?

Mavyret is a combination therapy consisting of glecaprevir and pibrentasvir. Glecaprevir is an NS3/4A protease inhibitor, and pibrentasvir is an NS5A inhibitor. These components work together to block the replication of the hepatitis C virus (HCV) by targeting essential viral proteins [3].

What is Mavyret used to treat?

Mavyret is a direct-acting antiviral (DAA) medication used for the treatment of chronic hepatitis C virus infection in adults. It is approved for all major genotypes of HCV (GT1-6) and can be used in patients with or without cirrhosis, including those with certain prior treatment experience [3].

When can generic versions of Mavyret become available?

Generic versions of Mavyret can potentially become available once its primary patents expire and any other market exclusivities have ended. The exact timing depends on the outcome of any patent litigation and regulatory approvals for generic applications. Based on current patent expiries, generic competition could emerge in the U.S. in late 2028 and in Europe in late 2029 [1].

What is the difference between loss of exclusivity and patent expiry?

Patent expiry is the date on which a drug's patent protection officially ends. Loss of exclusivity (LOE) is a broader term that refers to the point when a drug loses its market protection, which can be due to patent expiry, but also through other mechanisms like the expiration of regulatory exclusivities granted by health authorities (e.g., 5-year New Chemical Entity exclusivity in the US) or successful patent challenges [1][2]. Often, LOE aligns with patent expiry, but it can occur earlier or later depending on various factors.

What are the implications of Mavyret losing exclusivity?

The loss of exclusivity for Mavyret is likely to lead to increased competition from generic manufacturers. This competition typically results in lower drug prices, which can improve patient access and reduce healthcare costs [2].

Who are Mavyret's main competitors?

Mavyret competes in the market for hepatitis C treatments with other direct-acting antiviral regimens. Major competitors include Harvoni, Epclusa, and Zepatier, among others. The competitive landscape will continue to evolve as new treatments emerge and existing ones face generic competition [4].

What are the side effects of Mavyret?

The most common side effects reported with Mavyret include headache and fatigue [3]. Serious side effects are rare. Patients are advised to discuss potential side effects and their medical history with their healthcare provider before starting treatment [3].

Sources:
1. https://drugpatentwatch.com/
2. DrugPatentWatch.com proprietary data and analysis.
3. AbbVie. Mavyret Prescribing Information.
4. Various market analysis reports on the antiviral market.